Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression

NCT03965871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Depression

Interventions

DRUG: Esketamine DPI - low dose
DRUG: Esketamine DPI - medium dose
DRUG: Esketamine DPI - high dose
DRUG: Placebo DPI

Sponsor

Celon Pharma SA

Collaborators

[object Object]